Prognostic Markers for Survival in Mycosis Fundoides, Sézary Syndrome Identified

Share this content:
Newly identified prognostic markers may accurately stratify for survival in mycosis fundoides and Sézary syndrome.
Newly identified prognostic markers may accurately stratify for survival in mycosis fundoides and Sézary syndrome.

Newly identified prognostic markers may be able to accurately stratify for survival in patients with advanced-stage mycosis fundoides (MF) and Sézary syndrome (SS), according to a recent study that included the largest cohort of this patient population.1

Researchers led by Julia Scarisbrick, MBChBhons, FRCP, MD, of University Hospital Birmingham in the United Kingdom examined staging data of 1,275 patients with advanced MF/SS from 29 international specialist centers, with varying markers measured against overall survival risk.

“Published prognostic studies in MF/SS have been single-center trials,” the authors noted. “Because of the rarity of MF/SS, only a large collaboration would power a study to identify independent prognostic markers.”

Median overall survival was found to be 63 months, with 2-year survival at 77% and 5-year survival at 52%.

RELATED: Brentuximab Vedotin Active, Well-tolerated in Cutaneous T-Cell Lymphoma

Among the 10 markers that were assessed, 4 of them (stage 4 disease, age over 60 years, large-cell transformation, and increased lactate dehydrogenase) were found to be independent prognostic markers for worse survival.

Upon combining those factors in a prognostic index model, 5-year survival was found to be 68% in low-risk patients, 44% in intermediate patients, and 28% in high-risk patients.

Reference

  1. Scarisbrick JJ, Prince HM, Vermeer MH, et al. Cutaneous Lymphoma International Consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: effect of specific prognostic markers on survival and development of a prognostic model. J Clin Oncol. [published online ahead of print October 5, 2015]. doi: 10.1200/JCO.2015.61.7142.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters